Key facts
- This page summarizes Arjun Agarwal's Form 3 filing for Oruka Therapeutics, Inc. (ORKA).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 06 Sep 2024, 17:01.
Arjun Agarwal - 29 Aug 2024 Form 3 Insider Report for Oruka Therapeutics, Inc. (ORKA)
- Reporting relationship
- SVP, Finance and Treasurer
- Issuer ticker
- ORKA
- Reported as of
- 29 Aug 2024
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 06 Sep 2024, 17:01:37 UTC
- Next SEC filing
- 24 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Paul Quinlan, as attorney-in-fact for Arjun Agarwal
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Arjun Agarwal filed Form 3 for Oruka Therapeutics, Inc. (ORKA) on 06 Sep 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ORKA
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 128,566
- Exercise price
- $5.16
- Footnotes
- F1
ORKA
holding
Derivative
Warrant (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 85,711
- Exercise price
- $7.80
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This option represents a right to purchase 128,566 shares of the Issuer's common stock, one quarter of which will vest on March 22, 2025, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Footnote F2
This warrant represents a right to purchase 85,711 shares of the Issuer's common stock, one quarter of which will vest on April 3, 2025, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
SEC remarks
Exhibit 24 - Power of Attorney